论文部分内容阅读
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS]-3.2). Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24→0.37), or 0.37 mg/kg/week. Final height was evaluated in 50 patients at study completion (mean treatment duration, 6.5 years). Patients who received 0.37 mg/kg/week (n = 72) experienced a significantly greater increase in height velocity than those who received 0.24 mg/kg/-week (n = 70) (treatment difference = 0.8 cm/year; P =.003) or 0.24→0.37 mg/kg/week (n = 67) (treatment difference = 0.9 cm/year; P =.001). For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups. For the primary comparison between the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, the mean treatment difference (adjusted for differences in baseline predicted height SDS) was 0.57 SDS (3.6 cm; P =.025). Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, respectively, without dose effects on safety parameters. Final height measurementswere within the normal adult height range for 94%of patients randomized to 0.37 mg/kg/week who continued to final height. GHtreatment dose-dependently increases height velocity and final height in childrenwith idiopathic short stature.
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2). Patients were treated with GH at 0.24 mg / kg / week, 0.24 mg / kg / week for the first year and at 0.37 mg / kg / week thereafter (0.24 → 0.37), or 0.37 mg / kg / week. Patients who received 0.37 mg / kg / week (n = 72) experienced a significantly greater increase in height velocity than those who who received 0.24 mg / kg / -week (n = 70) (treatment difference = 0.8 cm / year; P = .003) or 0.24 → 0.37 mg / kg / week (n = 67) (treatment difference = 0.9 cm / year; P = .001). For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups. For the primary co The mean treatment difference (adjusted for differences in baseline predicted height SDS) was 0.57 SDS (3.6 cm; P = .025). Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg / kg / week and 0.24 mg / kg / week dose groups, respectively, without dose effects on safety parameters. Final height measurementswere within the normal adult height range for 94% of patients randomized to 0.37 mg / kg / week who continued to final height. GHtreatment dose-dependently increases only height velocity and final height in children with idiopathic short stature.